Evicenter
MarkdownMedical informationP&T meetings
Envudeucitinib (ESK-001)

Moderate-to-severe plaque psoriasis

Also known as FTP-637
Manufacturer
Alumis
Launch
Not announced
Last updated
277 sources

Clinical evidence

ONWARD1

57 evidence topics · 14 sources

Objective
Location and study date
Country removed from the ClinicalTrials.gov record
FieldQuoted record
Removed location countries (removedCountries)“Belgium”
Study design
Eligibility criteria
Treatment
Arms and interventions in the ClinicalTrials.gov record
Study outcomes
Rationale for using PASI 75 and sPGA 0/1 response as the co-primary endpoints
Secondary outcomes in the ClinicalTrials.gov record
Secondary outcome measureMeasure descriptionTime frame
“To compare the Psoriasis Area and Severity Index (PASI-90 and PASI-100) between ESK-001 and placebo or apremilast”“Proportion of participants achieving of ≥90% or 100% reduction in PASI”“24 weeks”
“To compare the Psoriasis Area and Severity Index (PASI-75) between ESK-001 and apremilast”“Proportion of participants achieving of ≥75% reduction in PASI”“24 weeks”
“To compare the Static Physician's Global Assessment (sPGA-0/1) between ESK-001 and apremilast”“Proportion of participants achieving a score of 0 or 1 on sPGA”“24 weeks”
“To compare the affected body surface area (%BSA) between ESK-001 and placebo or apremilast”“Change from baseline in %BSA”“24 weeks”
“To compare the scalp specific Physician's Global Assessment (ssPGA) between ESK-001 and placebo or apremilast.”“Proportion of participants achieving a score of 0 or 1 on ssPGA”“24 weeks”
“To compare the Psoriasis Symptoms and Signs Diary (PSSD) between ESK-001 and placebo or apremilast”“Proportion of participants achieving a score of 0”“24 weeks”
“To compare the Dermatology Life Quality Index (DLQI) between ESK-001 and placebo or apremilast”“Proportion of participants achieving a score of 0 or 1”“24 weeks”
“To compare the Pruritus numeric rating scale (NRS) between ESK-001 and placebo”“Change from baseline in Pruritus NRS”“24 weeks”
“Proportion of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)”“Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)”“24 weeks”
“To characterize the pharmacokinetics of ESK-001”“Maximum [Cmax] and minimum [Cmin] plasma concentration”“24 weeks”
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition

No evidence found.

Baseline characteristics
Baseline demographics and disease characteristics by arm in ONWARD1
CharacteristicEnvudeucitinib 40 mg BID, n = 459Placebo, n = 230Apremilast 30 mg BID, n = 223
Age, years, mean (SD)“49.1 (13.4)”“49.2 (13.3)”“47.7 (11.8)”
Age group, ≥65 years, n (%)“61 (13.3)”“27 (11.7)”“15 (6.7)”
Sex, male, n (%)“300 (65.4)”“156 (67.8)”“152 (68.2)”
Race, White, n (%)“358 (78.0)”“182 (79.1)”“177 (79.4)”
Race, Asian, n (%)“68 (14.8)”“28 (12.2)”“30 (13.5)”
Race, other, n (%)“33 (7.2)”“20 (8.7)”“16 (7.2)”
Weight, kg, mean (SD)“90.4 (24.0)”“91.0 (24.3)”“88.9 (21.0)”
BMI, kg/m2, mean (SD)“30.6 (7.2)”“30.6 (7.2)”“29.8 (6.5)”
Duration of disease, years, mean (SD)“19.9 (13.5)”“19.5 (13.3)”“17.2 (11.8)”
PASI, mean (SD)“20.4 (8.0)”“19.9 (7.5)”“20.3 (6.9)”
sPGA of 4, n (%)“129 (28.1)”“57 (24.8)”“61 (27.4)”
BSA % affected, mean (SD)“25.8 (15.8)”“26.2 (16.0)”“25.2 (14.9)”
DLQI, mean (SD)“10.6 (6.5)”“10.1 (6.7)”“10.8 (6.8)”
Worst pruritus NRS, mean (SD)“6.1 (2.7)”“6.0 (2.7)”“6.3 (2.6)”
Prior systemic psoriasis treatment, n (%)“221 (48.1)”“113 (49.1)”“107 (48.0)”
Baseline itch and scalp involvement by arm in ONWARD1
CharacteristicEnvudeucitinib 40 mg BID, N = 459Placebo, N = 230Apremilast 30 mg BID, N = 223
Worst pruritus NRS ≥1, n (%)“420 (91.5)”“210 (91.3)”“210 (94.2)”
Worst pruritus NRS ≥4, n (%)“353 (76.9)”“175 (76.1)”“176 (78.9)”
ss-PGA ≥3, n“274”“135”“150”
Worst pruritus NRS ≥4 and ss-PGA ≥3, n (%)“213 (77.7)”“102 (75.6)”“124 (82.7)”
Efficacy results
Co-primary and secondary endpoint results of ONWARD1 and ONWARD2 at topline

“Envudeucitinib met all primary and secondary endpoints with high statistical significance in ONWARD1 and ONWARD2.” (opens the source at this quote in a new tab)

“In each of these trials, envudeucitinib achieved superior skin clearance compared with placebo (p < 0.0001) on the co-primary endpoints of Psoriasis Area and Severity Index (PASI) 75 and static Physician’s Global Assessment (sPGA) 0/1 at Week 16.” (opens the source at this quote in a new tab)

“On average across both ONWARD1 and ONWARD2, 74% of patients achieved PASI 75 and 59% of patients achieved sPGA 0/1, with responses deepening over time.” (opens the source at this quote in a new tab)

“In addition, the placebo-adjusted response rates for the co-primary endpoints were consistent between the two trials.” (opens the source at this quote in a new tab)

“At Week 24, on the higher hurdle skin clearance measures, approximately 65% of patients achieved PASI 90, and more than 40% achieved PASI 100, on average across both trials.” (opens the source at this quote in a new tab)

“Rapid responses were observed, with clear separation from placebo on PASI 90 as early as Week 4.” (opens the source at this quote in a new tab)

“Envudeucitinib also achieved superior skin clearance compared with apremilast in each trial (p<0.0001) on all PASI endpoints at Week 24.” (opens the source at this quote in a new tab)

PASI 75, PASI 90, and PASI 100 response rates at week 16 in ONWARD1
Week 16 response, %Envudeucitinib 40 mg BID, n = 459Placebo, n = 230Apremilast 30 mg BID, n = 223
PASI 75 (co-primary endpoint)“76.5”“18.7”“44.4”
PASI 90“59.9”“4.8”“21.5”
PASI 100“29.4”“0.9”“4.0”
PASI 75, PASI 90, and PASI 100 response rates at week 24 in ONWARD1
Week 24 response, %Envudeucitinib 40 mg BID, n = 459Apremilast 30 mg BID, n = 223
PASI 75“78.6”“46.2”
PASI 90“68.0”“25.6”
PASI 100“41.0”“8.5”
Treat-to-target PASI and BSA thresholds in a post hoc analysis of ONWARD1 and ONWARD2

“To evaluate the achievement of clinically relevant treat-to-target thresholds for PASI and BSA in a post hoc analysis of ONWARD1 and ONWARD2” (opens the source at this quote in a new tab)

“Absolute PASI thresholds (0, ≤1, and ≤3) and BSA (≤3% and ≤1%) were calculated post hoc and assessed at Week 16 (vs placebo and apremilast) and Week 24 (vs apremilast)” (opens the source at this quote in a new tab)

“Patients who discontinued or had missing data were imputed as nonresponders” (opens the source at this quote in a new tab)

“Least squares (LS) means and corresponding 95% CIs for percent change from baseline in PASI total score were estimated using a mixed model with repeated measures (MMRM) with modified baseline observation carried forward (mBOCF) imputation; nominal P-values for treatment comparisons are presented at Weeks 16 and 24” (opens the source at this quote in a new tab)

“At Week 16, significantly more patients treated with envudeucitinib achieved clinically meaningful PASI treatment targets (Figure 3) and BSA treatment targets (Figure 4) vs placebo and apremilast” (opens the source at this quote in a new tab)

“Responses continued to improve through Week 24 for all thresholds” (opens the source at this quote in a new tab)

“Improvement in PASI from baseline with envudeucitinib was evident at Week 2 (Figure 6)” (opens the source at this quote in a new tab)

“Patients receiving envudeucitinib met stringent treat-to-target thresholds associated with disease control, with response rates increasing from Weeks 16 to 24” (opens the source at this quote in a new tab)

Efficacy by prior biologic exposure or body weight

No evidence found.

Health-related quality of life and patient-reported outcomes
Itch response at week 2, itch resolution at week 16, and responses through week 24 in ONWARD1 and ONWARD2
Safety results
Pooled ONWARD1 and ONWARD2 adverse events through weeks 16 and 24
Outcome, n (%)Week 16: envudeucitinib 40 mg BID, n = 890Week 16: placebo, n = 441Week 16: apremilast 30 mg BID, n = 438Week 24: envudeucitinib 40 mg BID only, n = 890Week 24: placebo to envudeucitinib 40 mg BID, n = 390Week 24: overall envudeucitinib 40 mg BID, n = 1280Week 24: apremilast 30 mg BID, n = 438
At least 1 TEAE“524 (58.9)”“166 (37.6)”“223 (50.9)”“563 (63.3)”“130 (33.3)”“693 (54.1)”“248 (56.6)”
At least 1 SAE“19 (2.1)”“5 (1.1)”“5 (1.1)”“24 (2.7)”“1 (0.3)”“25 (2.0)”“6 (1.4)”
TEAE leading to treatment discontinuation“30 (3.4)”“7 (1.6)”“9 (2.1)”“31 (3.5)”“4 (1.0)”“35 (2.7)”“12 (2.7)”
TEAE grade ≥3“42 (4.7)”“14 (3.2)”“18 (4.1)”“48 (5.4)”“7 (1.8)”“55 (4.3)”“23 (5.3)”
Nasopharyngitis“64 (7.2)”“21 (4.8)”“16 (3.7)”“92 (10.3)”“18 (4.6)”“110 (8.6)”“26 (5.9)”
Headache“92 (10.3)”“11 (2.5)”“40 (9.1)”“97 (10.9)”“11 (2.8)”“108 (8.4)”“42 (9.6)”
Upper respiratory tract infection“43 (4.8)”“7 (1.6)”“16 (3.7)”“57 (6.4)”“2 (0.5)”“59 (4.6)”“21 (4.8)”
Acne“53 (6.0)”“3 (0.7)”“3 (0.7)”“60 (6.7)”“17 (4.4)”“77 (6.0)”“3 (0.7)”
Nausea“20 (2.2)”“4 (0.9)”“23 (5.3)”“20 (2.2)”“0”“20 (1.6)”“23 (5.3)”
Diarrhea“14 (1.6)”“11 (2.5)”“36 (8.2)”“16 (1.8)”“1 (0.3)”“17 (1.3)”“36 (8.2)”
Herpes zoster and creatine phosphokinase elevations

No evidence found.

Study limitations
Summary
  • ONWARD1 results are available from company press releases, a company webcast presentation, and congress materials (Blauvelt et al., Hawkes et al., Ehst et al.). The ClinicalTrials.gov record reads “No Results Posted” and records a certification/extension first submitted on 2026-08-06.
  • Placebo control lasted 16 weeks, after which placebo participants rolled over to envudeucitinib; the week 24 PASI results compare envudeucitinib with apremilast alone.
  • The report holds no participant disposition by arm, no efficacy by prior biologic exposure or body weight, and no herpes zoster or creatine phosphokinase data. Safety, itch, and DLQI results are reported only for ONWARD1 and ONWARD2 pooled.
  • The sources differ on itch: the congress presentation places the mean decrease of more than 4 points in worst pruritus NRS by week 12 and a press release by week 16; at week 16, NRS 0 is reported as over one-third (itch poster) and about 40% (press release), and NRS 0/1 as more than half and approximately 60%.
  • Prior treatment is reported on different measures: prior systemic treatment by arm in 221 (48.1%), 113 (49.1%), and 107 (48.0%) participants (congress presentation), and, averaged across both trials, “Over 40% prior systemic use” and approximately 25% prior biologic use (webcast presentation). The report holds no prior biologic use by arm.
  • The itch analysis reports nominal P-values, and the PASI and BSA treat-to-target thresholds were calculated post hoc.
  • Eligibility excluded participants with lack of clinical response to a TYK2, IL-12, or IL-23 targeted treatment and those with recent or recurrent herpes zoster or herpes simplex infection.
  • The webcast presentation lists Belgium among the countries of study ESK-001-016, and the ClinicalTrials.gov API record for NCT06586112 lists Belgium as a removed location country.